Added to YB: 2025-08-04
Pitch date: 2025-07-31
NOVO-B.CO [neutral]
Novo Nordisk A/S
+9.14%
current return
Author Info
Summit Stocks shares weekly in-depth articles on the best stocks and insights into their portfolio. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 294.26
Price Target
514.37 (+60%)
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
growth
Novo Nordisk Just Lost $60 Billion in Market Cap
NOVO-B.CO (earnings update): 20% 5yr revenue CAGR (28% last 2yrs) at $44B scale; stock fell 26% on sales warning & CEO change. Growth slowing to 8-14% (from 16-24%), profit 10-16% (from 19-27%) due to US Ozempic/Wegovy slowdown & compounded GLP-1 issues. Strong ROIC ~40%, $10B capex. New CEO from int'l ops. Fwd P/E ~10, valuation 399 DKK vs 325 current.
Read full article (2 min)